Conquering 'snail fever': Schistosomiasis and its control in China

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 4, 2009, Pages 473-485

  McManus, Donald P ^a   Li, Yuesheng ^b   Gray, Darren J ^a   Ross, Allen G ^c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b HUNAN INSTITUTE OF PARASITIC DISEASES   (China)

^c GRIFFITH UNIVERSITY   (Australia)

Author keywords

China; Control; Diagnosis; Drug treatment; Epidemiology; Genetics and susceptibility; Pathogenesis; Schistosomiasis; Vaccines

Indexed keywords

ARTEMETHER; ASPARTIC PROTEINASE; CALPAIN; FATTY ACID BINDING PROTEIN; FERRITIN; GLUTATHIONE TRANSFERASE; METRIFONATE; OXAMNIQUINE; PARAMYOSIN; PRAZIQUANTEL; PROTEIN 14 3 3; SCHISTOSOMA VACCINE; SERINE PROTEINASE INHIBITOR; TETRASPANIN; TRIOSEPHOSPHATE ISOMERASE; VERY LOW DENSITY LIPOPROTEIN RECEPTOR; ANTHELMINTIC AGENT; VACCINE;

ANTIBODY DETECTION; CHINA; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG MECHANISM; FECES ANALYSIS; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; NEUROSCHISTOSOMIASIS; NONHUMAN; PARASITE TRANSMISSION; PATHOGENESIS; RECTUM BIOPSY; REVIEW; RISK FACTOR; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS; SINGLE DRUG DOSE; VACCINATION; VACCINE PRODUCTION; ANIMAL; DISEASE CARRIER; GENETIC PREDISPOSITION; ISOLATION AND PURIFICATION; SCHISTOSOMIASIS JAPONICA;

ANIMALS; ANTHELMINTICS; CHINA; DISEASE VECTORS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PRAZIQUANTEL; SCHISTOSOMIASIS JAPONICA; VACCINES;

EID: 67650100823     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.17     Document Type: Review

References (75)

1. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 368, 1106-1118 (2006).
2. Ross AG, Sleigh AC, Li Y et al. Schistosomiasis in the People's Republic of China: prospects and challenges for the 21st century. Clin. Microbiol. Rev. 14, 270-295 (2001).
3. Ross AG, Bartley PB, Sleigh AC et al. Schistosomiasis. N. Engl. J. Med. 346, 1212-1220 (2002).
4. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365, 1561-1569 (2005).
5. Utzinger J, Zhou XN, Chen MG, Bergquist R. Conquering schistosomiasis in China: the long march. Acta Trop. 96, 69-96 (2005).
6. Zhou XN, Wang LY, Chen MG et al. The public health significance and control of schistosomiasis in China - then and now. Acta Trop. 96, 97-105 (2005).
7. Fan K, Lai H. Mao Zedong's fight against schistosomiasis. Perspect. Biol. Med. 51, 176-187 (2008).
8. Wang L, Utzinger J, Zhou X-N. Schistosomiasis control: experiences and lessons from China. Lancet 372, 1793-1795 (2008).
9. Zhou XN, Guo JG, Wu XH et al. Epidemiology of schistosomiasis in the People's Republic of China, 2004. Emerg. Infect. Dis. 13, 1470-1476 (2007).
10. Ross AG, Vickers D, Olds GR, Shah SM, McManus DP. Katayama syndrome. Lancet Infect. Dis. 7, 218-224 (2007).
11. Bartley PB, Ramm GA, Jones MK, Ruddell RG, Li Y, McManus DP. A contributory role for activated hepatic stellate cells in the dynamics of Schistosoma japonicum egg-induced fibrosis. Int. J. Parasitol. 36, 993-1001 (2006).
12. Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, Wynn TA. Immunopathology of schistosomiasis. Immunol. Cell. Biol. 85, 148-154 (2007).
13. Wynn TA, Thompson RW, Cheever AW, Mentink-Kane MM. Immunopathogenesis of schistosomiasis. Immunol. Rev. 201, 156-167 (2004).
14. Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, McManus DP. Immunopathogenesis of human schistosomiasis. Parasite Immunol. 31, 163-176 (2009).
15. Zhu YC. Immunodiagnosis and its role in schistosomiasis control in China: a review. Acta Trop. 96, 130-136 (2005).
16. Lier T, Simonsen GS, Wang T et al. Low sensitivity of the formol-ethyl acetate sedimentation concentration technique in low-intensity Schistosoma japonicum infections. PLoS Negl. Trop. Dis. 3, e386 (2009).
17. Ellis MK, Li Y, Hou X, Chen H, McManus DP. sTNFR-II and sICAM-1 are associated with acute disease and hepatic inflammation in schistosomiasis japonica. Int. J. Parasitol. 38, 717-723 (2008).
18. Doenhoff MJ, Pica-Mattoccia L. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert Rev. Anti Infect. Ther. 4, 199-210 (2006).
19. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr. Opin. Infect. Dis. 21, 659-667 (2009).
20. Xiao SH. Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemesinins. Acta Trop. 96, 153-167 (2005).
21. Utzinger J, Xiao SH, Tanner M, Kaiser J. Artemisinins for schistosomiasis and beyond. Curr. Opin. Investig. Drugs 8 105-116 (2007).
22. Sayed AA, Simeonov A, Thomas CJ, Inglese J, Austin CP, Williams DL. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat. Med. 14, 407-412 (2008).
23. Keiser J, Chollet J, Xiao SH et al. Mefloquine-an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl. Trop. Dis. 3, e350 (2009).
24. Li YS, Chen H, He H, Hou X, Ellis M, McManus DP. A double-blind field trial on the effects of artemether on Schistosoma japonicum infection in a highly endemic focus in southern China. Acta Trop. 96, 184-190 (2005).
25. Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nat. Rev. Immunol. 2, 499-511 (2002).
26. Abath FG, Morais CN, Montenegro CE, Wynn TA, Montenegro SM. Immunopathogenic mechanisms in schistosomiasis: what can be learnt from human studies? Trends Parasitol. 22, 85-91 (2006).
27. Wynn TA, Thompson RW, Cheever AW, Mentink-Kane MM. Immunopathogenesis of schistosomiasis. Immunol. Rev. 201, 156-167 (2004).
28. McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin. Microbiol. Rev. 21, 225-242 (2008).
29. Capron A, Riveau GJ, Bartley PB, McManus DP. Prospects for a schistosome vaccine. Curr. Drug Targets Immune Endocr. Metab. Disord. 2, 281-290 (2002).
30. Mountford AP. Immunological aspects of schistosomiasis. Parasite Immunol. 27, 243-246 (2005).
31. Capron AG, Riveau GJ, Capron M, Trottein F. Schistosomes: the road from host - parasite interactions to vaccines in clinical trials. Trends Parasitol. 21, 143-149 (2005).
32. Bergquist R, Utzinger J, McManus DP. Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl. Trop. Dis. 2, e244 (2008).
33. Al-Sherbiny M, Osman A, Barakat R et al. In vitro cellular and humoral responses to Schistosoma mansoni vaccine candidate antigens. Acta Trop. 88, 117-130 (2003).
34. Acosta LP, Waine G, Aligui GD et al. Immune correlate study on human Schistosoma japonicum in a well-defined population in Leyte, Philippines: II. Cellular immune responses to S. japonicum recombinant and native antigens. Acta Trop. 84, 137-149 (2002).
35. Tran MH, Pearson MS, Bethony JM et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat. Med. 12, 835-840 (2006).
36. McManus DP, Dalton JP. Vaccines against the zoonotic trematodes Schistosoma japonicum, Fasciola hepatica and Fasciola gigantica. Parasitology 133, S43-S61 (2006).
37. Wang T, Zhang S, Wu W et al. Treatment and reinfection of water buffaloes and cattle infected with Schistosoma japonicum in Yangtze River Valley, Anhui Province, China. J. Parasitol. 92, 1088-1091 (2006).
38. Gray DJ, Williams GM, Li YS et al. A cluster-randomized bovine intervention trial against Schistosoma japonicum in the People's Republic of China: design and baseline results. Am. J. Trop. Med. Hyg. 77, 866-874 (2007).
39. Gray DJ, Williams GM, Li YS, McManus DP. Transmission dynamics of Schistosoma japonicum in the lakes and marshlands of China. PLoS ONE 3, e4058 (2008).
40. Wu XH, Wang XH, Utzinger J et al. Spatio-temporal correlation between human and bovine, schistosomiasis in China: insight from three nationwide surveys. Geospat. Health 2, 75-84 (2007).
41. McManus DP. Prospects for development of a transmission blocking vaccine against Schistosoma japonicum. Parasite Immunol. 27, 297-308 (2005).
42. Wilson RA, Coulson PS. Schistosome vaccines: a critical appraisal. Mem. Inst. Oswaldo Cruz 101(Suppl. 1), 13-20 (2006).
43. Wu ZD, Lü ZY, Yu XB. Development of a vaccine against Schistosoma japonicum in China: a review. Acta Trop. 96, 106-116 (2005).
44. Da'Dara AA, Li YS, Xiong T et al. DNA-based vaccine protects against zoonotic schistosomiasis in water buffalo. Vaccine 26, 3617-3625 (2008).
45. Hu W, Yan Q, Shen DK et al. Evolutionary and biomedical implications of a Schistosoma japonicum complementary DNA resource. Nat. Genet. 35, 139-147 (2003).
46. Verjovski-Almeida S, DeMarco R, Martins EA et al. Transcriptome analysis of the acoelomate human parasite Schistosoma mansoni. Nat. Genet. 35, 148-157 (2003).
47. Hu W, Brindley PJ, McManus DP, Feng Z, Han ZG. Schistosome transcriptomes: new insights into the parasite and schistosomiasis. Trends Mol. Med. 10, 217-225 (2004).
48. Liu F, Lu J, Hu W et al. New perspectives on host parasite interplay by comparative transcriptomic and proteomic analyses of the human blood fluke Schistosoma japonicum. PLoS Pathog. 2, e29 (2006).
49. Wilson RA, Ashton PD, Braschi S et al. 'Oming in on schistosomes: prospects and limitations for postgenomics. Trends Parasitol. 23, 14-20 (2007).
50. Brindley PJ, Pearce EJ. Genetic manipulation of schistosomes. Int. J. Parasitol. 37, 465-473 (2007).
51. Loukas A, Tran M, Pearson MS. Schistosome membrane proteins as vaccines. Int. J. Parasitol. 37, 257-263 (2007).
52. Cai P, Bu L, Wang J, Wang Z, Zhong X, Wang H. Molecular characterization of Schistosoma japonicum tegument protein tetraspanin-2: sequence variation and possible implications for immune evasion. Biochem. Biophys. Res. Commun. 372, 197-202 (2008),
53. Bergquist NR, Leonardo LR, Mitchell GF. Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach? Trends Parasitol. 21, 112-117 (2005).
54. Blanton RE, Salam EA, Ehsan A, King CH, Goddard KA. Schistosomal hepatic fibrosis and the interferon γ receptor: a linkage analysis using single-nucleotide polymorphic markers. Eur. J. Hum. Genet. 13, 660-668 (2005).
55. Campino S, Kwiatkowski D, Dessein A. Mendelian and complex genetics of susceptibility and resistance to parasitic infections. Semin. Immunol. 18, 411-422 (2006).
56. Chevillard C, Moukoko CE, Elwali NE et al. IFN-γ polymorphisms (IFN-γ +2109 and IFN-γ +3810) are associated with severe hepatic fibrosis in human hepatic schistosomiasis (Schistosoma mansoni). J. Immunol. 171, 5596-5601 (2003).
57. Dessein AJ, Hillaire D, Elwali NE et al. Severe hepatic fibrosis in Schistosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-γ receptor gene. Am. J. Hum. Genet. 65, 709-721 (1999).
58. Ellis MK, Li Y, Rong Z, Chen H, McManus DP. Familial aggregation of human infection with Schistosoma japonicum in the Poyang Lake region, China. Int. J. Parasitol. 36, 71-77 (2006).
59. Ellis MK, Zhao ZZ, Chen HG, Montgomery GW, Li YS, McManus DP. Analysis of the 5q31-q33 locus shows an association between single nucleotide polymorphism variants in the IL-5 gene and symptomatic infection with the human blood fluke, Schistosoma japonicum. J. Immunol. 179, 8366-8371 (2007).
60. Marquet S, Abel L, Hillaire D et al. Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. Nat. Genet. 14, 181-184 (1996).
61. Marquet S, Abel L, Hillaire D, Dessein A. Full results of the genome-wide scan which localises a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. Eur. J. Hum. Genet. 7, 88-97 (1999).
62. He H, Isnard A, Kouriba B et al. A STAT6 gene polymorphism is associated with high infection levels in urinary schistosomiasis. Genes Immun. 9, 195-206 (2008).
63. Henri S, Chevillard C, Mergani A et al. Cytokine regulation of periportal fibrosis in humans infected with Schistosoma mansoni: IFN-γ is associated with protection against fibrosis and TNF-α with aggravation of disease. J. Immunol. 169, 929-936 (2002).
64. Chevillard C, Henri S, Stefani F, Parzy D, Dessein A. Two new polymorphisms in the human interferon γ (IFN-γ) promoter. Eur. J. Immunogenet. 29, 53-56 (2002).
65. Arnaud V, Li J, Wang Y et al. Regulatory role of interleukin-10 and interferon-γ in severe hepatic central and peripheral fibrosis in humans infected with Schistosoma japonicum. J. Infect. Dis. 198, 418-426 (2008).
66. Wang L-D, Chen H-G, Guo J-G et al. A strategy to control transmission of Schistosoma japonicum in China. N. Engl. J. Med. 360, 122-123 (2009).
67. Finkelstein JL, Schleinitz MD, Carabin H, McGarvey ST. Decision-model estimation of the age-specific disability weight for schistosomiasis japonica: a systematic review of the literature. PLoS Negl. Trop. Dis. 2, e158 (2008).
68. Raso G, Matthys B, N'Goran EK, Tanner M, Vounatsou P, Utzinger J. Spatial risk prediction and mapping of Schistosoma mansoni infections among schoolchildren living in western Côte d'Ivoire. Parasitology 131, 97-108 (2005).
69. Guo JG, Vounatsou P, Cao CL et al. A geographic information and remote sensing based model for prediction of Oncomelania hupensis habitats in the Poyang Lake area, China. Acta Tropica 96, 213-222 (2005).
70. Seto EY, Wu W, Liu HY et al. Impact of changing water levels and weather on Oncomelania hupensis hupensis populations, the snail host of Schistosoma japonicum, downstream of the Three Gorges Dam. Ecohealth 5, 149-158 (2008).
71. Li YS, Sleigh AC, Ross AG et al. A two-year epidemiological survey in China provides epidemiological evidence for human resistance to re-infection by Schistosoma japonicum. Ann. Trop. Med. Parasitol. 93, 629-642 (1999).
72. Williams GM, Sleigh AC, Li Y et al. Mathematical modelling of schistosomiasis japonica: comparison of control strategies in the Peoples' Republic of China. Acta Trop. 82, 253-262 (2002).
73. Li YS, Raso G, Zhao ZY, He YK, Ellis MK, McManus DP. Large water management projects and schistosomiasis control, Dongting Lake region, China. Emerg. Infect. Dis. 13, 973-979 (2007).
74. Zhu HM, Xiang S, Yang K, Wu XH, Zhou XN. Three Gorges Dam and its impact on the potential transmission of schistosomiasis in regions along the Yangtze River. Eco Health 5, 137-148 (2008).
75. Yang GJ, Vounatsou P, Zhou XN, Tanner M, Utzinger J. A potential impact of climate change and water resource development on the transmission of Schistosoma japonicum in China. Parassitologia 47, 127-134 (2005).